{
  "id": "665c9ae67f85be56",
  "title": "IGC Pharma Reaches 70 % Enrollment in Phase 2 CALMA Trial Evaluating IGC - AD1 for Alzheimer Agitation",
  "description": "20260202T153000Z",
  "content": "",
  "source": "hawaiitelegraph.com",
  "source_url": "http://www.hawaiitelegraph.com/news/278844574/igc-pharma-reaches-70-enrollment-in-phase-2-calma-trial-evaluating-igc-ad1-for-alzheimer-agitation",
  "published_at": "20260202T153000Z",
  "fetched_at": "2026-02-03T00:29:56.519436+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "llm"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.hawaiitelegraph.com/news/278844574/igc-pharma-reaches-70-enrollment-in-phase-2-calma-trial-evaluating-igc-ad1-for-alzheimer-agitation",
    "url_mobile": "",
    "title": "IGC Pharma Reaches 70 % Enrollment in Phase 2 CALMA Trial Evaluating IGC - AD1 for Alzheimer Agitation",
    "seendate": "20260202T153000Z",
    "socialimage": "",
    "domain": "hawaiitelegraph.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}